| Full text | |
| Author(s): |
Castro dos Santos, Nidia C.
[1, 2, 3]
;
Andere, Naira M. R. B.
[1, 4]
;
Araujo, Cassia F.
[1, 4]
;
de Marco, Andrea C.
[1, 4]
;
Kantarci, Alpdogan
[2]
;
Van Dyke, Thomas E.
[2]
;
Santamaria, Mauro P.
[1, 4]
Total Authors: 7
|
| Affiliation: | [1] Unesp Sao Paulo State Univ, Inst Sci & Technol, Div Periodont, Ave Engn Francisco Jose Longo 777, BR-12245000 Sao Jose Dos Campos, SP - Brazil
[2] Forsyth Inst, Ctr Clin & Translat Res, Cambridge, MA - USA
[3] Univ Guarulhos, Dent Res Div, Guarulhos, SP - Brazil
[4] Castro dos Santos, Nidia C., Univ Guarulhos, Dent Res Div, Guarulhos, SP, Brazil.Castro dos Santos, Nidia C., Unesp Sao Paulo State Univ, Inst Sci & Technol, Div Periodont, Ave Engn Francisco Jose Longo 777, BR-12245000 Sao Jose Dos Campos, SP - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | Journal of Periodontology; v. 91, n. 10 JUN 2020. |
| Web of Science Citations: | 1 |
| Abstract | |
Background Supplementation with omega-3 polyunsaturated fatty acids (omega-3 PUFA) and low-dose aspirin (ASA) have been proposed as a host modulation regimen to control chronic inflammatory diseases. The aim of this study was to investigate the clinical and immunological impact of orally administered omega-3 PUFA and ASA as adjuncts to periodontal debridement for the treatment of periodontitis in patients type 2 diabetes. Methods Seventy-five patients (n = 25/group) were randomly assigned to receive placebo and periodontal debridement (CG), omega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months)afterperiodontal debridement (test group {[}TG]1), or omega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months)beforeperiodontal debridement (TG2). Periodontal parameters and GCF were collected at baseline (t0), 3 months after periodontal debridement and omega-3 PUFA + ASA or placebo for TG1 and CG (t1), after omega-3 PUFA + ASA (before periodontal debridement) for TG2 (t1), and 6 months after periodontal debridement (all groups) (t2). GCF was analyzed for cytokine levels by multiplex ELISA. Results Ten patients (40%) in TG1 and nine patients (36%) in TG2 achieved the clinical endpoint for treatment (less than or equal to four sites with probing depth >= 5 mm), as opposed to four (16%) in CG. There was clinical attachment gain in moderate and deep pockets for TG1. IFN-gamma and interleukin (IL)-8 levels decreased over time for both test groups. IL-6 levels were lower for TG1. HbA1c levels reduced for TG1. Conclusion Adjunctive omega-3 and ASA after periodontal debridement provides clinical and immunological benefits to the treatment of periodontitis in patients with type 2 diabetes. (AU) | |
| FAPESP's process: | 16/02234-7 - Effect of É-3 polyunsaturated fatty acids plus low dose of aspirin daily supplementation as adjunctive to full-mouth ultrasonic debridement for the treatment of chronic periodontitis in type 2 diabetic patients. Superiority randomized clinical trial |
| Grantee: | Nidia Cristina Castro dos Santos |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 17/21136-9 - Immunological actions of daily supplementation of omega-3 polyunsaturated fatty acids plus low-dose aspirin as an adjunct to periodontal debridement for the treatment of chronic periodontitis in patients with type 2 diabetes |
| Grantee: | Nidia Cristina Castro dos Santos |
| Support Opportunities: | Scholarships abroad - Research Internship - Doctorate |